Literature DB >> 17468661

Valganciclovir for congenital CMV infection: a pilot study on plasma concentration in newborns and infants.

Luisa Galli1, Andrea Novelli, Elena Chiappini, Paola Gervaso, Maria Iris Cassetta, Stefania Fallani, Maurizio de Martino.   

Abstract

The pharmacokinetics of valganciclovir were studied in 8 infants ranging in age from 4 to 90 days (mean 20 days). We suggest that doses of 15 mg/kg given twice daily may be suitable for neonates and young infants.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17468661     DOI： 10.1097/01.inf.0000261111.90075.4d

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  6 in total

1.  Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir.

Authors:  Jacob Amir; Dana G Wolf; Itzhak Levy
Journal:  Eur J Pediatr       Date:  2010-03-16       Impact factor: 3.183

2.  Pyrosequencing allows the detection of emergent ganciclovir resistance mutations after HCMV infection.

Authors:  Susanne E Kampmann; Birgit Schindele; Luise Apelt; Christoph Bührer; Lars Garten; Katharina Weizsaecker; Detlev H Krüger; Bernhard Ehlers; Jörg Hofmann
Journal:  Med Microbiol Immunol       Date:  2010-12-17       Impact factor: 3.402

3.  Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection.

Authors:  G Lombardi; F Garofoli; P Villani; M Tizzoni; M Angelini; M Cusato; L Bollani; A De Silvestri; M Regazzi; M Stronati
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-09-11       Impact factor: 3.267

Review 4.  Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.

Authors:  Jessica K Roberts; Chris Stockmann; Jonathan E Constance; Justin Stiers; Michael G Spigarelli; Robert M Ward; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

Review 5.  Antivirals for cytomegalovirus infection in neonates and infants: focus on pharmacokinetics, formulations, dosing, and adverse events.

Authors:  Beth C Marshall; William C Koch
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

6.  The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein-Barr virus disease.

Authors:  Heather E Vezina; Richard C Brundage; Thomas E Nevins; Henry H Balfour
Journal:  Clin Pharmacol       Date:  2009-12-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.